trending Market Intelligence /marketintelligence/en/news-insights/trending/W2feitc3Pdbf-LjN_TkB4A2 content esgSubNav
In This List

CTI BioPharma plans public offering of preferred stock

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


CTI BioPharma plans public offering of preferred stock

CTI BioPharma plans to sell series N-3 convertible preferred stock at $1,000 apiece in an underwritten public offering.

The company said it plans to use net proceeds for the development and marketing approval of its bone marrow drug pacritinib, as well other clinical trials and general corporate purposes.

Jefferies LLC will act as the sole book-running manager for the offering, which will be priced at a later date.